Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pralnacasan (vertex pharmaceuticals).

Britta Siegmund1, Martin Zeitz

  • 1Universitatsklinikum Benjamin Franklin, Medizinische Klinik I, Freie Universitat Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. britta.siegmund@medizin.fu-berlin.de

Idrugs : the Investigational Drugs Journal
|June 6, 2003
PubMed
Summary

Vertex and Aventis Pharma are developing pralnacasan, an interleukin-1b converting enzyme (ICE) inhibitor. This collaboration focuses on potential treatments for various inflammatory diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifrequency tabletop magnetic resonance elastography for ex-vivo characterization of murine intestinal tissue biomechanics.

Journal of the mechanical behavior of biomedical materials·2026
Same author

Aligning patient and planetary health: planetary health diet adherence and inflammatory bowel disease prognosis across Western and Eastern cohorts.

NPJ science of food·2026
Same author

[Updated S3 guideline on ulcerative colitis].

Zeitschrift fur Gastroenterologie·2026
Same author

Mesenteric Adipose Tissue as a Modulator of Intestinal Inflammation: Mechanistic Insights and Model Systems in Crohn's Disease.

European journal of immunology·2026
Same author

Coordinated Interferon-γ/Tumor Necrosis Factor axis Drives Selective Loss of Activated Enteric Glia in Inflammatory Bowel Diseases.

Cellular and molecular gastroenterology and hepatology·2026
Same author

IBDome: An Integrated Molecular, Histopathological, and Clinical Atlas of Inflammatory Bowel Diseases.

Gastroenterology·2026

Area of Science:

  • Biotechnology
  • Pharmacology
  • Immunology

Background:

  • Inflammatory diseases involve complex biological pathways.
  • Interleukin-1 beta (IL-1b) is a key mediator in inflammatory processes.
  • Inhibiting IL-1b converting enzyme (ICE) is a therapeutic strategy for inflammation.

Purpose of the Study:

  • To report on the collaborative development of pralnacasan.
  • To highlight pralnacasan as an interleukin (IL)-1b converting enzyme (ICE) inhibitor.
  • To investigate the potential of pralnacasan in treating inflammatory conditions.

Main Methods:

  • Drug development collaboration between Vertex and Aventis Pharma AG.
  • Focus on ICE inhibitor mechanism of action.
  • Preclinical and clinical investigations for inflammatory disease treatment.

Main Results:

  • Pralnacasan identified as a promising ICE inhibitor.
  • Successful collaboration progressing the drug candidate.
  • Demonstrated potential for treating inflammatory diseases.

Conclusions:

  • Pralnacasan shows therapeutic potential for inflammatory diseases.
  • The Vertex-Aventis collaboration advances ICE inhibitor development.
  • Further research is warranted to establish clinical efficacy.

Related Experiment Videos